Body composition and sarcopenia: The next-generation of personalized oncology and pharmacology? - Université Paris Cité Accéder directement au contenu
Article Dans Une Revue Pharmacology & Therapeutics Part A Chemotherapy Toxicology and Metabolic Inhibitors Année : 2019

Body composition and sarcopenia: The next-generation of personalized oncology and pharmacology?

Résumé

Body composition has gained increasing attention in oncology in recent years due to fact that sarcopenia has been revealed to be a strong prognostic indicator for survival across multiple stages and cancer types and a predictive factor for toxicity and surgery complications. Accumulating evidence over the last decade has unraveled the "pharmacology" of sarcopenia. Lean body mass may be more relevant to define drug dosing than the "classical" body surface area or flat-fixed dosing in patients with cancer. Since sarcopenia has a major impact on patient survival and quality of life, therapeutic interventions aiming at reducing muscle loss have been developed and are being prospectively evaluated in randomized controlled trials. It is now acknowledged that this supportive care dimension of oncological management is essential to ensure the success of any anticancer treatment. The field of sarcopenia and body composition in cancer is developing quickly, with (i) the newly identified concept of sarcopenic obesity defined as a specific pathophysiological entity, (ii) unsolved issues regarding the best evaluation modalities and cutoff for definition of sarcopenia on imaging, (iii) first results from clinical trials evaluating physical activity, and (iv) emerging body-composition-tailored drug administration schemes. In this context, we propose a comprehensive review providing a panoramic approach of the clinical, pharmacological and therapeutic implications of sarcopenia and body composition in oncology.

Domaines

Cancer
Fichier principal
Vignette du fichier
PT#23432 Hilmi et al. Manuscript final.pdf (842.58 Ko) Télécharger le fichier
PT#23432 Hilmi et al. Figure 1. Overlap and distinctions between sarcopenia, cachexia and malnutrition (1).pdf (140.66 Ko) Télécharger le fichier
PT#23432 Hilmi et al. Figure 2.pdf (139.28 Ko) Télécharger le fichier
Loading...

Dates et versions

hal-02325334 , version 1 (24-10-2019)

Identifiants

Citer

Marc Hilmi, Anne Jouinot, Robert Burns, Frédéric Pigneur, Rémi Mounier, et al.. Body composition and sarcopenia: The next-generation of personalized oncology and pharmacology?. Pharmacology & Therapeutics Part A Chemotherapy Toxicology and Metabolic Inhibitors, 2019, 196, pp.135-159. ⟨10.1016/j.pharmthera.2018.12.003⟩. ⟨hal-02325334⟩
70 Consultations
338 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More